The march toward malaria vaccines.
暂无分享,去创建一个
S. Hoffman | J. Vekemans | T. Richie | P. Duffy | Thomas L Richie | Johan Vekemans | Patrick E Duffy | Stephen L Hoffman
[1] J. Harty,et al. CD8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge. , 2009, Vaccine.
[2] S. Hoffman,et al. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine , 2003, Journal of Experimental Biology.
[3] J. Shiver,et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex , 2006, Proceedings of the National Academy of Sciences.
[4] S. Hoffman,et al. Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites , 2014, The American journal of tropical medicine and hygiene.
[5] S. Hoffman,et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Hoffman,et al. Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein1 , 2004, The Journal of Immunology.
[7] J. Aguiar,et al. Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies , 2009, PloS one.
[8] D. Doolan,et al. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. , 2007, Vaccine.
[9] Patricia De la Vega,et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.
[10] J. Weber,et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. , 1987, Science.
[11] R. Sauerwein,et al. A Plant-Produced Pfs25 VLP Malaria Vaccine Candidate Induces Persistent Transmission Blocking Antibodies against Plasmodium falciparum in Immunized Mice , 2013, PloS one.
[12] S. Hoffman,et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. , 2004, Vaccine.
[13] R. Carter,et al. Target antigens in malaria transmission blocking immunity. , 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[14] Randall L. Kincaid,et al. Heterologous Protein Expression Is Enhanced by Harmonizing the Codon Usage Frequencies of the Target Gene with those of the Expression Host , 2008, PloS one.
[15] M. Nussenzweig,et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites , 2006, Nature.
[16] P. Palese,et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Ghani,et al. The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection , 2013, PloS one.
[18] Kwaku Poku Asante,et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine , 2014, BMC Medicine.
[19] V. Nussenzweig,et al. γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites , 1987, Nature.
[20] J. Sattabongkot,et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. , 2005, Vaccine.
[21] R. Cortese,et al. Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals , 2014, The Journal of infectious diseases.
[22] Adrian J F Luty,et al. Protection against a malaria challenge by sporozoite inoculation. , 2009, The New England journal of medicine.
[23] A. Jin,et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. , 2013, Vaccine.
[24] P. Chomez,et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.
[25] M. Fay,et al. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.
[26] A. Folgori,et al. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector , 2012, The Journal of infectious diseases.
[27] Hong Zhou,et al. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. , 2007, Vaccine.
[28] K. Sell,et al. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. , 1974, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[29] J. Sadoff,et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. , 1995, The Journal of infectious diseases.
[30] Joe D. Cohen,et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.
[31] P. Gething,et al. Transmission-blocking interventions eliminate malaria from laboratory populations , 2013, Nature Communications.
[32] S. Hoffman,et al. SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE , 1987, The Lancet.
[33] R. Cortese,et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[34] Bjoern Peters,et al. Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes , 2014, PloS one.
[35] Ogobara K. Doumbo,et al. A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.
[36] E. R. James,et al. Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity , 2011, Science.
[37] D. Carucci,et al. DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.
[38] A. Aly,et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design , 2009, Proceedings of the National Academy of Sciences.
[39] E. Jaffee,et al. A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction , 2011, Clinical Cancer Research.
[40] S. Hoffman,et al. Protection of Rhesus Macaques against Lethal Plasmodium knowlesi Malaria by a Heterologous DNA Priming and Poxvirus Boosting Immunization Regimen , 2002, Infection and Immunity.
[41] J. Vanderberg,et al. Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei , 1967, Nature.
[42] A. Folgori,et al. Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines , 2010, The Journal of Immunology.
[43] S. Kappe,et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. , 2013, Vaccine.
[44] Myron M. Levine,et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites , 1987, Nature.
[45] B. Greenwood,et al. Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites , 2014, PLoS medicine.
[46] R. Longley,et al. Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[47] Kevin Marsh,et al. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines , 2014, BMC Medicine.
[48] G. van Gemert,et al. Long Term Protection after Immunization with P. berghei Sporozoites Correlates with Sustained IFNγ Responses of Hepatic CD8+ Memory T Cells , 2012, PloS one.
[49] K. Legge,et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly , 2010, Proceedings of the National Academy of Sciences.
[50] R. Gwadz. Successful immunization against the sexual stages of Plasmodium gallinaceum. , 1976, Science.
[51] Kwaku Poku Asante,et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. , 2010, The Journal of infectious diseases.
[52] Photini Sinnis,et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host , 2011, The Journal of experimental medicine.
[53] Christian Stemberger,et al. CD8alpha+ dendritic cells are required for efficient entry of Listeria monocytogenes into the spleen. , 2006, Immunity.
[54] Peter G. Smith,et al. MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. , 2009, Vaccine.
[55] A. Vaughan,et al. Malaria parasite development in the mosquito and infection of the mammalian host. , 2009, Annual review of microbiology.
[56] L. Wood,et al. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy , 2014, Front. Cell. Infect. Microbiol..
[57] S. Kappe,et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[58] S. Hoffman,et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.
[59] A. Hill,et al. Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure , 2014, PloS one.
[60] A. Folgori,et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation , 2013, Nature Communications.
[61] Kevin Marsh,et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. , 2013, The New England journal of medicine.
[62] R. Carter,et al. Anti-gamete monoclonal antibodies synergistically block transmission of malaria by preventing fertilization in the mosquito. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[63] Conor P. Cahill,et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa , 2011, Malaria Journal.
[64] D. Kaslow,et al. Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. , 2014, Vaccine.
[65] Sumana Chakravarty,et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.
[66] S. Hoffman,et al. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. , 2013, Vaccine.
[67] S. Hoffman,et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.
[68] S. Hoffman,et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.
[69] Mario Roederer,et al. Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.
[70] Nicolas Maire,et al. What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines , 2008, PloS one.
[71] A. Hill,et al. Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge , 2007, Infection and Immunity.
[72] S. Hoffman,et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.
[73] Anil K Ghosh,et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen , 2007, Proceedings of the National Academy of Sciences.
[74] V. A. Stewart,et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.
[75] S. Hoffman,et al. Two Plasmodium 6‐Cys family‐related proteins have distinct and critical roles in liver‐stage development , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[76] D. Webster,et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans , 2003, Nature Medicine.
[77] S. Hoffman,et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA , 2012, Human vaccines & immunotherapeutics.
[78] Edward B. Miller,et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection , 2013, Human vaccines & immunotherapeutics.
[79] J. Palensky,et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.
[80] S. Hoffman,et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.
[81] S. Hoffman,et al. Codon Optimization of Gene Fragments EncodingPlasmodium falciparum Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice , 2001, Infection and Immunity.
[82] Pedro Alonso,et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. , 2011, The New England journal of medicine.
[83] S. Hoffman,et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[84] S. Hoffman,et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. , 2012, Vaccine.
[85] S. Hoffman,et al. Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe , 2013, PloS one.
[86] Kwaku Poku Asante,et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.
[87] P. Duffy,et al. Pre-erythrocytic malaria vaccines: identifying the targets , 2012, Expert review of vaccines.
[88] G. van Gemert,et al. Cytotoxic Markers Associate With Protection Against Malaria in Human Volunteers Immunized With Plasmodium falciparum Sporozoites , 2014, The Journal of infectious diseases.
[89] A. Nicosia,et al. Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[90] Kwaku Poku Asante,et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. , 2011, The Lancet. Infectious diseases.
[91] R. Sinden,et al. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. , 2010, Vaccine.
[92] R. Sauerwein,et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study , 2011, The Lancet.
[93] Virander S. Chauhan,et al. Bacterially Expressed Full-Length Recombinant Plasmodium falciparum RH5 Protein Binds Erythrocytes and Elicits Potent Strain-Transcending Parasite-Neutralizing Antibodies , 2013, Infection and Immunity.
[94] J. Vanderberg,et al. Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.
[95] G. van Gemert,et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity , 2013, Proceedings of the National Academy of Sciences.
[96] D. Doolan,et al. Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses , 2012, PloS one.
[97] D. Kaslow,et al. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. , 2001, Experimental parasitology.
[98] R. Carter,et al. Malaria transmission blocked by immunisation with gametes of the malaria parasite , 1976, Nature.